Evidence map›Paper›PMID 34324163›Full record

ArticleJournal of endocrinological investigation2022

Clinical value of functional thyrotropin receptor antibodies in Serbian patients with Graves' orbitopathy.

M Sarić Matutinović, T Diana, B Nedeljković Beleslin, J Ćirić, M Žarković, G J Kahaly, S Ignjatović

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Anti-nuclear autoantibodies in Graves' disease and Graves' orbitopathy.Journal of endocrinological investigation · 2023
    Article
  11. Review
  12. Current concepts regarding Graves' orbitopathy.Journal of internal medicine · 2022
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

M Sarić MatutinovićFaculty of Pharmacy, University of Belgrade, Belgrade, Serbia. marija.saric@pharmacy.bg.ac.rs.ORCID http://orcid.org/0000-0001-7591-8885
T DianaMolecular Thyroid Research Laboratory, Department of Medicine I, Johannes Gutenberg University (JGU) Medical Center, Mainz, Germany.
B Nedeljković BeleslinClinic of Endocrinology, University Clinical Center of Serbia, Belgrade, Serbia.
J ĆirićClinic of Endocrinology, University Clinical Center of Serbia, Belgrade, Serbia.
M ŽarkovićClinic of Endocrinology, University Clinical Center of Serbia, Belgrade, Serbia.
G J Kahaly *Molecular Thyroid Research Laboratory, Department of Medicine I, Johannes Gutenberg University (JGU) Medical Center, Mainz, Germany.
S Ignjatović *Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
University of Belgrade · RSJohannes Gutenberg University Mainz · DE

Funding

Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja 175036/451-03-9/2021-14/200161
6 · The paper itself

Abstract

purposeThyrotropin receptor autoantibodies (TSH-R-Ab) are heterogeneous in their biological function and play a significant role in the pathophysiology of both Graves' disease and Graves' orbitopathy (GO). The clinical significance and utility of determining functional TSH-R-Ab in a Serbian collective were evaluated.

methods91 consecutive patients with GO were included in this study. Total TSH-R-Ab concentration, referred to as TSH-R binding inhibitory immunoglobulins (TBII) was detected using a competitive-binding immunoassay. Stimulating and blocking TSH-R-Ab (TSAb and TBAb) were measured with cell-based bioassays.

resultsStimulating TSAb activity and TBII positivity were detected in 85 of 91 (93.4%) and 65 of 91 (71.4%) patients with GO (P < 0.001). Blocking TBAb activity was observed in only one patient who expressed dual stimulating and blocking TSH-R-Ab activity. The sensitivity rates for differentiating between clinically active versus inactive and mild versus moderate-to-severe GO were 100% and 100% for TSAb, respectively. In contrast, these were 82% and 87% only for TBII. Seven of eight (87.5%) and one of eight (12.5%) euthyroid patients with GO were TSAb and TBII positive, respectively (P < 0.031). TSAb serum levels significantly predicted GO activity compared to TBII (odds ratio, OR, 95%CI: 3.908, 95%CI 1.615-9.457, P = 0.003; versus 2.133, 0.904-5.032, P = 0.084, univariate analysis; and OR 4.341, 95%CI 1.609-11.707, P = 0.004; versus 2.337, 0.889-6.145, P = 0.085 multivariate analysis).

conclusionStimulating TSAb are highly prevalent in patients with GO and show superior clinical characteristics and predictive potential compared to the traditionally used TBII.

Indexed as

AutoantibodiesGraves DiseaseGraves OphthalmopathyImmunoglobulins, Thyroid-StimulatingFemaleHumansImmunoassayMaleMiddle AgedReceptors, ThyrotropinSerbiaThyroid HormonesAutoantibodiesImmunoglobulins, Thyroid-StimulatingReceptors, ThyrotropinThyroid HormonesAutoimmune thyroid diseasesBioassayDiseaseFunctional thyrotropin receptor antibodiesGravesOrbitopathyStimulatory antibodies

Identifiers

PMID34324163
OpenAlexW3186240069

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.